An Encouraging Update For High-Risk Non-Hodgkin Lymphoma
- A new clinical trial tested adding two targeted medicines — tafasitamab and lenalidomide — to standard treatment, known as R‑CHOP, for patients with higher-risk diffuse large B‑cell lymphoma (DLBCL). Patients who received the new combination had a 25% lower risk of their cancer progressing.
- Side effects were considered manageable, though infections and low white or red blood cell counts were more common in the group that received tafasitamab and lenalidomide + R-CHOP.
- This reflects a growing shift in lymphoma care: using immune-based treatments earlier, when the chance of a cure is highest.
- R‑CHOP has long been the standard treatment for DLBCL, but research in the New England Journal of Medicine shows it only cures about 60% of patients, leaving many in need of better options.
A new trial found that adding two targeted drugs, tafasitamab and lenalidomide, to the standard treatment plan helped patients with higher-risk DLBCL live longer without their cancer progressing.
Read MoreThe FrontMIND Trial: Addressing An Unmet Need
DLBCL is a fast-growing blood cancer that starts in white blood cells called B-cells. Because it grows quickly, it often responds well to treatment — but the standard regimen, R‑CHOP (which includes several chemotherapy drugs, a targeted therapy, and a steroid), only cures about 60% of patients. Roughly 4 in 10 people will see their cancer come back.The frontMIND trial tested whether adding two targeted drugs to R‑CHOP could improve outcomes for higher-risk DLBCL patients. The drugs were:
- Tafasitamab: A targeted antibody that finds and attacks cancer cells
- Lenalidomide: An immune-boosting drug that helps the body fight cancer
The core idea was to bring these treatments in earlier — right at diagnosis, before the cancer has a chance to become resistant.
WATCH: B-Cell Lymphoma: What’s Your Type?
Patients who received the combination had a 25% lower risk of their cancer growing, coming back, or causing death compared to those who got R‑CHOP alone. Side effects were considered manageable, though infections and low white or red blood cell counts were more common in the group that received tafasitamab and lenalidomide.
“If you’re curing more patients, you’re generally willing to accept a bit more toxicity,” Dr. Leonard notes.
Evolving Treatment Options For Lymphoma
FrontMIND reflects a broader shift in lymphoma care: using immune-based therapies earlier, rather than saving them as a last resort.
Two other treatments reshaping the field include bispecific antibodies, which bring immune cells and cancer cells together so the immune system can destroy the cancer directly, and CAR T‑cell therapy, which reprograms a patient’s own immune cells to recognize and attack cancer.
“We’re getting away from everybody getting the same treatment. Directing the right therapy to the right patient should improve efficacy and reduce unnecessary toxicity,” Dr. Leonard explains.
If the early results hold up, frontMIND could lead to a a new standard of care for high-risk DLBCL.
Expert Resources for Diffuse B-Cell Lymphoma Patients
- Diffuse Large B-Cell Lymphoma Relapse: Don’t Rush—The Right Plan Matters
- Diffuse Large B-Cell Lymphoma and CAR T-Cell Therapy: When to Seek a Second Opinion
- ‘This Is Really Practice-Changing’: New Therapy Provides Hope for More Patients With Large B-Cell Lymphoma
- CAR T-Cell Therapy Explained: What Diffuse Large B-Cell Lymphoma Patients Should Know
The Future of DLBCL Treatment
Large B-cell lymphoma (LBCL) is the most common type of non-Hodgkin lymphoma — a cancer that starts in immune cells called lymphocytes. The most common subtype, DLBCL, grows quickly but often responds well to prompt treatment.
R-CHOP is the standard treatment for aggressive non-Hodgkin lymphoma, given in six cycles spaced three weeks apart.
WATCH: Non-Hodgkin Lymphoma: It’s More Than Just One Type
R-CHOP stands for:
- Rituximab: A targeted drug that helps your immune system find and destroy cancer cells
- Cyclophosphamide: A chemotherapy drug
- Doxorubicin: A chemotherapy drug
- Vincristine: A chemotherapy drug
- Prednisone: A steroid that reduces inflammation
WATCH: What is R-CHOP? What does it do?
Common side effects of R-CHOP include fatigue, hair loss, mouth sores, increased infection risk, and appetite changes.
When researchers added tafasitamab and lenalidomide for the frontMIND trial, there were slightly more serious side effects and more people had to discontinue part of treatment compared to those who received R-CHOP alone (25.7% v. 17.9%).
Questions To Ask Your Doctor
- What type of lymphoma do I have?
- Would I benefit from an approach like adding tafasitamab and lenalidomide to my treatment plan?
- Am I eligible for this treatment approach?
- What are the risks v. benefits of adding tafasitamab and lenalidomide?
- What are my options if side effects become unmanageable?
Learn more about SurvivorNet's rigorous medical review process.
